The cost-effectiveness of introducing infant rotavirus vaccination in Armenia in 2012 using Rotarix(R) was evaluated using a multiple birth cohort model. The model considered the cost and health implications of hospitalisations, primary health care consultations and episodes not leading to medical care in children under five years old. Rotavirus vaccination is expected to cost the Ministry of Health 220,000in2012,risingto830,000 in 2016 following termination of GAVI co-financing, then declining to 260,000in2025duetovaccinepricematurity.Itmayreducehealthcarecostsby34,000 in the first year, rising to 180,000by2019.By2025,vaccinationmaybeclosetocostsavingtotheMinistryofHealthifthevaccinepurchasepricedeclinesasexpected.Oncecoveragehasreachedhighlevels,vaccinationmayprevent25,000cases,3000primarycareconsultations,1000hospitalisationsand8deathsperbirthcohortvaccinated.Thecostperdisability−adjustedlifeyear(DALY)savedisestimatedtobeabout650 from the perspective of the Ministry of Health, 850includingcostsaccruedtoboththeMinistryandtoGAVI,820 from a societal perspective excluding indirect costs and 44fromasocietalperspectiveincludingindirectcosts.SincethegrossdomesticproductpercapitaofArmeniain2008was3800, rotavirus vaccination is likely to be regarded as "very cost-effective" from a WHO standpoint. Vaccination may still be "very cost-effective" if less favourable assumptions are used regarding vaccine price and disease incidence, as long as DALYs are not age-weighted